Clinical trials: Influenza Type A
Influenza
Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
This is a Phase 2a randomized, double-blind, placebo-controlled study designed to assess the safety and tolerability of an investigational monoclonal antibody, VIS410, in subjects with uncomplicated influenza.
- Trial name
- NCT02989194
- Testing
- VIS410 low dose, VIS410 high dose
- Where
- 54 sites in United States, Bulgaria and 5 more
- Volunteers
- 150 people
- Sponsor
- Visterra, Inc.
COVID - 19, Influenza A
Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test
This observational study aims to evaluate the diagnostic performance of an investigational Influenza A/B and COVID-19 test in patients presenting with signs and symptoms of respiratory infection.
- Conditions
- COVID - 19, Influenza A, Influenza B
- Trial name
- NCT07190131
- Testing
- Investigational Flu A/B And Covid-19 Diagnostic Test
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 588 people
- Sponsor
- iHealth Labs inc
Influenza
Swine Flu (Novel Influenza A H1N1) Vaccine Study
In the first half of this year a novel Influenza A H1N1 virus has resulted in an influenza pandemic. The United Kingdom has seen a particularly high incidence of disease.
- Trial name
- NCT00980850
- Testing
- Baxter Novel Influenza A H1N1 Whole Virus Vaccine, GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine
- Where
- 5 sites in United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers
Background: Influenza A H3N2 is a flu virus. Symptoms include fever, cough, and runny nose. It can also be more serious. Researchers want to know more about how influenza causes disease in people.
- Trial name
- NCT02594189
- Testing
- Live recombinantly derived A/Bethesda/MM1/H3N2 virus
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
H1N1 Influenza
The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A
Influenza continues to inflict an important burden on health-care systems. The 2009 H1N1 influenza virus first appeared in Mexico and the United States in March and April 2009 and has swept the globe with unprecedented speed.
- Trial name
- NCT01127282
- Testing
- Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Seoul National University Hospital
Influenza, Human
Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines
This study seeks to understand the host factors that affect the replication and immune response of seasonal and candidate pandemic live attenuated influenza vaccine (LAIV) in humans and to develop biomarkers that can predict the…
- Trial name
- NCT01674205
- Testing
- A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca), A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca), 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pandemic Influenza
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza
This aim of this project is to evaluate the efficacy of neuraminidase inhibitors in patients who have a clinical diagnosis of pandemic influenza infection. The study is observational only.
- Trial name
- PIPET A (NCT00640302)
- Where
- 8 sites in Australia
- Sponsor
- Kirby Institute
Influenza A Virus Infection, Influenza B Virus Infection
Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
The aim of this study is to evaluate the clinical efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections in China.
- Trial name
- NCT01459081
- Testing
- Zanamivir
- Where
- 12 sites in China
- Volunteers
- 298 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Influenza
H5N1 Vaccination With and Without AS03: Systems Biology Analysis
This is a single center, randomized, double-blinded, controlled, Phase I, small targeted prospective study in healthy male and non-pregnant female subjects, 18 to 49 years old, inclusive, designed to determine the safety…
- Trial name
- NCT01573312
- Testing
- ASO3 Adjuvant, Influenza A/H5N1 Vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A
Influenza Viral Challenge Study of CC-42344 in Healthy Participants
Participants in this study will be given either CC-42344 (one of two dose levels) or placebo orally for 5 days after receiving an influenza (flu) challenge virus.
- Trial name
- NCT06160531
- Testing
- CC-42344
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Cocrystal Pharma, Inc.
Influenza
H7N9 Mix and Match With MF59 in Healthy Adults
This is a Phase II randomized, double-blinded, controlled study in up to 700 males and non-pregnant females, 19 to 64 years old, inclusive, designed to assess the safety, reactogenicity, and immunogenicity of a monovalent…
- Trial name
- NCT01938742
- Testing
- Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59
- Where
- 4 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine
The aim of this study is to investigate the long-term immunogenicity and safety of the inactivated split-virion vaccine after one immunization.
- Trial name
- NCT01336166
- Testing
- split-virion, non-adjuvanted H1N1 vaccine of 15 μg, split-virion, non-adjuvanted H1N1 vaccine of 30 μg, split-virion, non-adjuvanted H1N1 vaccine of 45 μg
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza, Human
Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital
The purpose of this study is to determine whether zanamivir aqueous solution given by intravenous injection is safe in treating hospitalized patients with confirmed influenza infection.
- Trial name
- NCT01014988
- Testing
- zanamivir aqueous solution
- Where
- 110 sites in United States, Australia and 11 more
- Volunteers
- 202 people
- Sponsor
- GlaxoSmithKline
Pertussis, Diphtheria
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
Pediacel™ is currently licensed in the UK for use as a 3 dose regimen for the active immunisation of infants against Diphtheria, Tetanus, Pertussis, Poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00287092
- Testing
- DT5aP-IPV-Hib 5-component Pertussis vaccine, Infanrix® -IPV+Hib
- Where
- 14 sites in Finland, Sweden
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza
The objective of this study is to evaluate the safety of the vaccine and the immune response to the vaccine in healthy adult volunteers 65 years of age or older.
- Trial name
- AVX502-003 (NCT00706732)
- Testing
- AVX502
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
Atherosclerosis
Influenza A VIRus and Destabilization of Atherosclerotic Carotid Plaques
Atherosclerosis is the main cause of cardiovascular diseases and is characterized by the accumulation of lipids and inflammatory cells such as macrophages and lymphocytes within the vessel wall of large and medium-sized arteries…
- Trial name
- VIRAL (NCT06217471)
- Testing
- Carotid Endoarterectomy
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- IRCCS Policlinico S. Donato
Influenza
Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine
The purpose of this study is to determine whether having received an H5 vaccine in the past primes the immune system to respond rapidly to another dose of H5 vaccine.
- Trial name
- NCT00240903
- Testing
- Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2, Influenza, Human
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal…
- Conditions
- SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome
- Trial name
- NCT06684379
- Testing
- PRS CK STORM
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PEACHES BIOTECH
Influenza A
Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations
Every 1-2 years, the seasonal influenza vaccine composition changes to include updated viruses, yet the precise effects of updating the vaccine remain understudied.
- Trial name
- NCT06567860
- Testing
- Influenza Fluzone vaccine
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- La Jolla Institute for Immunology